13F-HR filed by Lynx1 Capital Management LP
Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 15 holding rows worth $385,811,394.
- Accession
- 0001892688-24-000060
- Filer
- CIK 1910456
- Filed
- 2024-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2024
A holdings report, 15 entries on the cover page, a total value of $385,811,394 stated on the cover page (in dollars after the unit check, H1), rows summing to $385,811,394 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerLynx1 Capital Advisors LLC028-22145
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 2,253,183 | $89,316,174 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 1,509,007 | $67,950,585 | dollars as filed | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 3,696,820 | $49,907,070 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 5,224,600 | $41,483,324 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 2,082,973 | $35,535,519 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 3,310,563 | $35,290,602 | dollars as filed | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 3,634,662 | $29,695,189 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 526,642 | $11,375,467 | dollars as filed | |
| AUTOLUS THERAPEUTICS PLC SPON | 05280R100 | COM | 1,390,160 | $8,869,221 | dollars as filed | |
| PASSAGE BIO INC | 702712100 | COM | 4,845,871 | $6,541,926 | dollars as filed | |
| KINNATE BIOPHARMA INC | 49705R105 | COM | 1,981,106 | $5,269,742 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268108 | COM | 2,068,842 | $1,932,712 | dollars as filed | |
| PIERIS PHARMACEUTICALS INC | 720795103 | COM | 8,779,162 | $1,608,342 | dollars as filed | |
| BIONOMICS LIMITED | 09063M205 | ADS | 814,467 | $838,901 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 17,400 | $196,620 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001892688-24-000060 | this filing | 2024-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001892688-24-000068 | added | 2024-05-30 | acceptance time not in the bulk data set |